Login Register Cart 0
Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Regulations and Reimbursement of Digital Therapeutics: A Review of Current Global Practices and Future Prospects

Author(s): Amit Dang*, Dimple Dang and Pawan Rane

Volume 8, Issue 2, 2021

Published on: 17 October, 2021

Article ID: e181021197286 Pages: 7

DOI: 10.2174/2667337108666211018101106

Price: $65

Abstract

The ever-increasing use of digital technologies is rapidly changing the face of modern healthcare delivery. Healthcare systems are embracing digital health solutions to improve patient outcomes, enhance healthcare delivery, and reduce costs. Digital therapeutics (DTx) are now a popular category of digital health solutions aimed at preventing, managing, or treating medical disorders. These evidence-based technologies/products either complement a conventional therapy or are prescribed as stand-alone treatments for a range of conditions, including chronic diseases and mental health disorders. Many pharmaceutical companies and healthcare start-ups are developing DTx products for different health conditions. Despite similarities between DTx and conventional medicines, DTx products are not covered under reimbursement at present in many countries. There are no uniform regulations for DTx prescription and reimbursement. This review aims to analyse the current DTx scenario, particularly highlighting the regulatory aspect and reimbursement of DTx products globally.

Keywords: Prescription digital therapeutics, DTx reimbursement, DTx regulations, DTx pricing models, DTx review, healthcare

Graphical Abstract

[1]
Dhilawala A. What is digital healthcare and how does it affect patient care? Galen Data 2019. Available from: https://www.galendata.com/digital-healthcare-future-heathcare/ (updated 18 Feb 2019; cited 20 Jul 2021).
[2]
Fried N. Pharmaceutical companies and digital health startups: It’s time to get together: mobihealthnews 2017. Available from: https://www.mobihealthnews.com/content/pharmaceutical-companies-and-digital-health-startups-it%E2%80%99s-time-get-together (updated 10 Feb 2017; cited 20 Jul 2021).
[3]
Norton M. How COVID-19 is highlighting the importance of digital health solutions 2020. 2020. Available from: https://www.med-technews.com/features/how-covid-19-is-highlighting-the-importance-of-digital-healt/ (updated 09 Jul 2020; cited 20 Jul 2021).
[4]
Webster P. Virtual health care in the era of COVID-19. Lancet 2020; 395(10231): 1180-1.
[http://dx.doi.org/10.1016/S0140-6736(20)30818-7] [PMID: 32278374]
[5]
Buenafe MG. FDA regulation of COVID-19 Apps, digital therapeutics, and other digital health technologies: Morgan Lewis 2020. Available from: https://www.morganlewis.com/pubs/2020/07/fda-regulation-of-covid-19-apps-digital-therapeutics-and-other-digital-health-technologies-cv19-lf (updated 28 Jul 2020; cited 20 Jul 2021).
[6]
Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. J Family Med Prim Care 2020; 9(5): 2207-13.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_105_20] [PMID: 32754475]
[7]
Lim H. The rise of digital therapeutics (DTx): Iqvia 2020. Available from: https://www.iqvia.com/locations/asia-pacific/blogs/2020/07/the-rise-of-digital-therapeutics-dtx(updated 06 Jul 2020; cited 20 Jul 2021).
[8]
Chung JY. Digital therapeutics and clinical pharmacology. Transl Clin Pharmacol 2019; 27(1): 6-11.
[http://dx.doi.org/10.12793/tcp.2019.27.1.6] [PMID: 32055575]
[9]
Bluestar 2020. Available from: https://www.welldoc.com/users/ (cited 20 Jul 2021).
[10]
Kamat T, Dang A, Dang D, Rane P. Impact of integrated medication reminders, gamification and financial rewards via smart phone application on treatment adherence in uncomplicated type II diabetes patients: a randomized, open-label trial. [Unpublished]. J Diabetol Accepted for publication May 21, 2021.
[11]
Kvedar JC, Fogel AL, Elenko E, Zohar D. Digital medicine’s march on chronic disease. Nat Biotechnol 2016; 34(3): 239-46.
[http://dx.doi.org/10.1038/nbt.3495] [PMID: 26963544]
[12]
Makin S. The emerging world of digital therapeutics. Nature 2019; 573(7775): S106-9.
[http://dx.doi.org/10.1038/d41586-019-02873-1] [PMID: 31554990]
[13]
Wolfson LJ, Castillo ME, Giglio N, et al. The use of antibiotics in the treatment of pediatric varicella patients: real-world evidence from the multi-country MARVEL study in Latin America & Europe. BMC Public Health 2019; 19(1): 826.
[http://dx.doi.org/10.1186/s12889-019-7071-z] [PMID: 31242875]
[14]
M health Fairview applauds PreferredOne as first in Minnesota to cover innovative prescription digital therapeutics to treat addiction: Business Wire 2020. Available from: https://www.businesswire.com/news/home/20200930005985/en/M-Health-Fairview-Applauds-PreferredOne-as-First-in-Minnesota-to-Cover-Innovative-Prescription-Digital-Therapeutics-to-Treat-Addiction (updated 30 Sept 2020; cited 20 Jul 2021).
[15]
Smok B, Franczak J, Domagalski K, Pawłowska M. Varicella complications in children one-site Polish population - a 19- year long survey. Przegl Epidemiol 2018; 72(4): 459-67.
[PMID: 30809999]
[16]
Dias AC, Rodrigues LR, Nunes AA, Castro SS. Impact of vaccination on the incidence of varicella hospitalizations in a state in Southeast Brazil. Rev Soc Bras Med Trop 2019; 52: e20190149.
[http://dx.doi.org/10.1590/0037-8682-0149-2019] [PMID: 31800919]
[17]
Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med 2020; 3(1): 159.
[http://dx.doi.org/10.1038/s41746-020-00370-8] [PMID: 33311567]
[18]
Galbraith S. Digital therapeutics: Augmenting patient health outcomes: AstraZeneca 2021. Available from: https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/digital-therapeutics-augmenting-patient-health-outcomes.html (published 15 June 2021; cited 20 Jul 2021).
[19]
Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J 2019; 6(2): 94-8.
[http://dx.doi.org/10.7861/futurehosp.6-2-94] [PMID: 31363513]
[20]
Lee SM, Lee D. Opportunities and challenges for contactless healthcare services in the post-COVID-19 Era. Technol Forecast Soc Change 2021; 167: 120712.
[http://dx.doi.org/10.1016/j.techfore.2021.120712] [PMID: 33654330]
[21]
Potential impact of prescription digital therapeutics: Managed Healthcare Executive 2021. Available from: https://www.managedhealthcareexecutive.com/view/potential-impact-of-prescription-digital-therapeutics (published 06 Jan 2021; cited 20 Jul 2021).
[22]
Dang A, Vallish BN. Can Health Technology Assessment (HTA) provide a solution to tackle the increasing health-care expenditure in India? Indian J Public Health 2016; 60(2): 138-41.
[http://dx.doi.org/10.4103/0019-557X.184570] [PMID: 27350708]
[23]
Vogenberg FR. Understanding pharmacy reimbursement. American Society of Health-System Pharmacists, 2006; pp. P763.
[24]
Health care systems: four basic models: PNHP 2010. Available from: https://www.pnhp.org/single_payer_resources/health_care_systems_four_basic_models.php
[25]
Hagemann C, Krämer A, Grote V, Liese JG, Streng A. Specific varicella-related complications and their decrease in hospitalized children after the introduction of general varicella vaccination: results from a multicenter pediatric hospital surveillance study in bavaria (Germany). Infect Dis Ther 2019; 8(4): 597-611.
[http://dx.doi.org/10.1007/s40121-019-00273-6] [PMID: 31674000]
[26]
Fontinelle A. Health reimbursement arrangement (HRA) 2020. Available from: https://www.investopedia.com/terms/h/hra.asp
[27]
Rutkowski T, Yang E, Bernath E, Coker T, Ricard M. Access and reimbursement: Access to digital therapeutics in a post- COVID-19 world. 2020. Available from: https://www.cbpartners.com/access-to-digital-therapeutics-in-a-post-covid-19-world/
[28]
Todorova TT. Varicella infection in a non-universally vaccinated population: Actual epidemiology in Bulgaria (2013-2015). J Infect Public Health 2018; 11(3): 326-30.
[http://dx.doi.org/10.1016/j.jiph.2017.09.023] [PMID: 29017751]
[29]
Digital therapeutic quality, access, and appropriate utilization matter.: DTA 2021. Available from: https://www.dtxalliance.org/
[30]
Licholai G. Digital therapeutics leaders focus on reimbursement 2020 2020. Available from: https://www.forbes.com/sites/greglicholai/2020/02/23/digital-therapeutics-leaders-focus-on-reimbursement/#284740cd4d0f
[31]
Ostrovsky A. Medicare should break an old rule to let breakthrough digital therapeutics save lives 2020. Available from: https://www.statnews.com/2020/10/19/medicare-proposed-rule-breakthrough-digital-therapeutics/
[32]
Cairns E. FDA tightens up digital health oversight: Evaluate Vantage 2020. Available from: https://www.evaluate.com/vantage/articles/news/policy-and-regulation/fda-tightens-digital-health-oversight
[33]
Staines R. FDA launches digital health center of excellence: Pharmaphorum 2020. Available from: https://pharmaphorum.com/news/fda-launches-digital-health-center-of-excellence/
[34]
The FDA’s digital health center of excellence: why it matters and what it means to you: Forbes 2020. Available from: https://www.forbes.com/sites/forrester/2020/10/29/the-fdas-digital-health-center-of-excellence-why-it-matters-and-what-it-means-to-you/?sh=57b453cc5685
[35]
Bernal JL, Hobbelen P, Amirthalingam G. Burden of varicella complications in secondary care, England, 2004 to 2017. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2019; 24(42): 1900233.
[36]
Gerke S, Stern AD, Minssen T. Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries. NPJ Digit Med 2020; 3: 94.
[http://dx.doi.org/10.1038/s41746-020-0306-7] [PMID: 32685700]
[37]
Health: Doctors in Germany allowed to prescribe digital apps for first time: The Local 2020. Available from: https://www.thelocal.de/20201006/health-doctors-in-germany-allowed-to-prescribe-digital-apps-for-first-time/amp
[38]
MHealthBelgium 2020. Available from: https://mhealthbelgium.be/
[39]
De Luca M. Design, validation and reimbursement of digital therapies: the state of the art in Italy: Digital Health Global 2019. Available from: https://www.digitalhealthglobal.com/design-validation-and-reimbursement-of-digital-therapies-the-state-of-the-art-in-italy/
[40]
Hyun-tai S. Seoul publishes English guides for digital therapeutics: Korea Biomedical Review 2020. Available from: http://www.koreabiomed.com/news/articleView.html?idxno=9554
[41]
Hyun-tai S. Regulator, associations explore new home guidelines for digital therapeutics: Korea Biomedical Review 2020. Available from: http://www.koreabiomed.com/news/articleView.html? idxno=9363
[42]
Mori P. Is digital health finally taking off in Japan? 2019. Available from: https://www.intralinkgroup.com/en-GB/News/Blog/April-2019/Is-digital-health-finally-taking-off-in-Japan
[43]
Gotanda M, Miyata T. Japan: digital health laws and regulations: ICLG 2021. Available from: https://iclg.com/practice-areas/digital-health-laws-and-regulations/japan
[44]
Digital therapeutics: A new ‘class of medicine’: EH News Bureau 2020. Available from: https://www.expresshealthcare.in/blogs/guest-blogs-healthcare/digital-therapeutics-a-new -class-of-medicine/416425/
[45]
National Health Authority- Government of India 2018. Available from: https://pmjay.gov.in/about/pmjay
[46]
Dang A, Dang D, Vallish BN. Importance of Evidence-Based Health Insurance Reimbursement and Health Technology Assessment for Achieving Universal Health Coverage and Improved Access to Health in India. Value Health Reg Issues 2021; 24: 24-30.
[http://dx.doi.org/10.1016/j.vhri.2020.04.007] [PMID: 33476860]
[47]
Lack of reimbursement will limit the impact of digital therapeutics in global healthcare market: Globaldata 2019. Available from: https://www.globaldata.com/lack-of-reimbursement-will-limit-the-impact-of-digital-therapeutics-in-global-healthcare-market/
[48]
Comstock J. With many regulatory barriers clear, remaining roadblocks for digital therapeutics are cultural, logistical: mobihealthnews 2020. Available from: https://www.mobihealthnews.com/news/emea/many-regulatory-barriers-clear-remaining-roadblocks-digital-therapeutics-are-cultural
[49]
Aboujaoude E, Gega L. From Digital Mental Health Interventions to Digital “Addiction”: Where the Two Fields Converge. Front Psychiatry 2020; 10: 1017.
[http://dx.doi.org/10.3389/fpsyt.2019.01017] [PMID: 32038336]
[50]
Lovett L. Digital therapeutics may not cause toxicity, but they're not entirely without risk: mobihealthnews 2019. Available from: https://www.mobihealthnews.com/news/north-america/digital-therapeutics-may-not-cause-toxicity-theyre-not-entirely-without-risk

Rights & Permissions Print Cite
Article Metrics
25
© 2024 Bentham Science Publishers | Privacy Policy